Moreover, PAX3 expression has emerged as a potential determinant of therapeutic sensitivity, with its levels significantly correlating with the responsiveness to multiple anti-tumor drugs, including vorinostat, doramapimod, linsitinib, and tamoxifen, among others (Figure 7N, Supplementary Figure S11). This evidence concerns the gene PAX3 and neoplasm.